Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Advanced Non-Small Cell Lung Cancer focused on measuring lung cancer, chemotherapy, vinorelbine, gemcitabine, carboplatin, advanced lung cancer, non-small cell lung cancer
Eligibility Criteria
Inclusion Criteria:
- Non-small cell lung cancer stage IIIB or IV
- Not eligible for radical radiotherapy or surgery
- WHO performance status 0-2
Exclusion Criteria:
- Pregnancy
- Other clinical active cancer disease
- ALAT/ALP more than 3 times upper normal limit, bilirubin >1.5 upper limit
- Bowel disease that causes malabsorption
Sites / Locations
- Øystein Fløtten
- Sverre Fluge
- Heidi Rolke
- Tore Amundsen
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
A
B
Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 All patients will receive a maximum of 3 courses with an interval of 3 weeks
Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert's formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 All patients will receive a maximum of 3 courses with an interval of 3 weeks